Logo do repositório
 
Publicação

Development and Application of a Harmonization Method for IgG Antibody Levels Against SARS-CoV-2S pike Protein: A Cohort Study in Healthcare Professionals

dc.contributor.authorSaraiva, Ana Leonor
dc.contributor.authorAfreixo, Vera
dc.contributor.authorGaio, Vânia
dc.contributor.authorMachado, Ausenda
dc.date.accessioned2026-03-04T15:21:06Z
dc.date.available2026-03-04T15:21:06Z
dc.date.issued2025-07-10
dc.description.abstractIntroduction: The emergence of COVID-19 led to the rapid development of vaccines and diagnostic tests. To assess antibody responses in healthcare workers (HCWs), a 2021–2022 cohort study was conducted in three Portuguese hospitals. Antibody levels were measured at six time points: pre-vaccination, post-first dose, at 3, 6, 12 months after the second dose, and post-booster. Each hospital utilized a different assay: Abbott’s CMIA, Roche’s Elecsys® ECLIA, and Siemens’ ADVIA Centaur®, leading to challenges in data comparability. The study aimed to harmonize serological data across these hospitals to enable joint analysis and better understand the dynamics of humoral immunity among HCWs in Portugal. Methods: To ensure adequate conversion of antibody titers obtained from different laboratory methods, several harmonization strategies were applied and compared. These included the World Health Organization (WHO) international conversion and a main strategy based on quantile interpolation, with linear and spline methods tested, followed by Deming regression. Before interpolation, models were required to estimate the antibody titers due to the limitations of each method, such as linear regressions with polynomials and splines, followed by data linearization and normalization. The final choice between methods was based on a graphical assessment of which approach best preserved the original data patterns prior to harmonization. Results: The application of quantile interpolation followed by regression proved more effective than the WHO recommended approach for harmonizing data across hospitals. This method preserved the individual distribution patterns of each hospital, even after transformation. Importantly, it allowed the harmonized values to reflect the scale and magnitude observed in the reference method (Abbott’s CMIA). After harmonization, a marked increase was observed between the pre-vaccination time point and the post-vaccination time point, followed by a gradual decrease over the next three time points. Finally, a second, even more pronounced increase was observed after the booster dose. Conclusions: Quantile interpolation followed by regression enabled effective harmonization of serological data across the hospital centers, allowing for the comparison and joint analysis of anti-SARS-CoV-2 IgG antibody titers from different laboratory methods. This approach also preserved the expected temporal antibody response pattern. Although laboratory validation, by quantifying the same samples across different laboratories, was not performed, which would be necessary to fully confirm the adequacy of the method, the presented methodology shows strong applicability to other contexts, particularly in European studies that conduct pooled analyses of data from multiple countries and laboratories.eng
dc.description.sponsorshipVEBIS Lot2
dc.identifier.urihttp://hdl.handle.net/10400.18/11135
dc.language.isoeng
dc.peerreviewedn/a
dc.rights.uriN/A
dc.subjectSARS-CoV-2
dc.subjectHarmonization
dc.subjectHealthcare Professionals
dc.subjectEstado de Saúde e de Doença
dc.subjectDeterminantes de Saúde
dc.subjectInfecções Respiratórias
dc.titleDevelopment and Application of a Harmonization Method for IgG Antibody Levels Against SARS-CoV-2S pike Protein: A Cohort Study in Healthcare Professionalseng
dc.typeconference object
dspace.entity.typePublication
oaire.citation.conferenceDate2025-07-10
oaire.citation.conferencePlaceAveiro, Portugal
oaire.citation.title7.º Encontro de Estatística na Tomada de Decisão em Saúde – Epidemiologia, 10, 11 julho 2025
oaire.versionhttp://purl.org/coar/version/c_be7fb7dd8ff6fe43
person.familyNameGaio
person.familyNameMachado
person.givenNameVânia
person.givenNameAusenda
person.identifier.ciencia-idA71A-17AF-30C7
person.identifier.ciencia-id1217-6076-5D88
person.identifier.orcid0000-0001-7626-4991
person.identifier.orcid0000-0002-1849-1499
person.identifier.scopus-author-id56080468200
relation.isAuthorOfPublication59791814-187c-4b34-b3a2-6ad67a213814
relation.isAuthorOfPublication544ad266-0c22-4a50-9ebc-86acc08d6666
relation.isAuthorOfPublication.latestForDiscovery59791814-187c-4b34-b3a2-6ad67a213814

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
Ana_L_Saraiva.pdf
Tamanho:
13.84 MB
Formato:
Adobe Portable Document Format
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição: